Drug intelligence / Profile preview

VB-1953

Development stage: Phase 2
Lead developer: Vyome Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

VB-1953 is a clinical-stage drug developed by Vyome Therapeutics Inc. It is a topical antifungal currently in Phase 2 development. The drug is being investigated for the treatment of inflammatory facial acne vulgaris, dandruff, and seborrheic dermatitis. It is formulated as a topical gel.

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on VB-1953.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB-1953.

Explore the full profile